Malignant pheochromocytoma in a 16-year-old patient with neurofibromatosis type 1

Research output: Contribution to journalArticlepeer-review


Patients with neurofibromatosis type I (NF1) feature a high risk of developing benign and malignant tumors, mainly those with a neuroectodermal origin, the risk being about 4 times higher than in the general population. Pheochromocytoma (PHEO) is a sporadic tumor (1:100 000) arising from the adrenal medulla. Pheochromocytoma is a rare condition when occurring in conjunction with NF1 and occurs in about 1% of patients, rarely in those of pediatric age. In this study we present a 16-year-old patient with NF1 and malignant PHEO. Loss of heterozygosity analysis in PHEOs shows a reduction to homozygosity, observed for both 17p and 17q markers. This case confirms the importance of surveillance for malignant neoplasias in NF1 patients during childhood and adolescence. On the other hand, since 30% of PHEOs had germline mutations and, more rarely, somatic mutations, patients with PHEO should be investigated for associated genetic syndromes.

Original languageEnglish
Pages (from-to)126-129
Number of pages4
JournalPediatric and Developmental Pathology
Issue number2
Publication statusPublished - 2014


  • Loss of heterozygosity
  • Malignant pheochromocytoma
  • Multicarcinoma syndromes
  • Neurofibromatosis type 1

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pathology and Forensic Medicine


Dive into the research topics of 'Malignant pheochromocytoma in a 16-year-old patient with neurofibromatosis type 1'. Together they form a unique fingerprint.

Cite this